FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases

Lara Maria Pasetto, Antonio Jirillo, Girolama Iadicicco, Elena Rossi, Myriam Katja Paris, Silvio Monfardini

Research output: Contribution to journalArticle

27 Citations (Scopus)

Abstract

Colorectal adenocarcinoma ranks second as a cause of death due to cancer in the Western world. Already at the time of the primary tumor, 15-25% of the patients present with liver metastases while another 20% will develop metastasis following treatment of the colorectal primary. Without any treatment the median survival after the detection of metastases is approximately 9 months, depending on the extent of the disease at the time of diagnosis. Clinical trials with the "FOLFOX and FOLFIRI families" of drugs, designed for the treatment of metastatic colorectal cancer, their results and the costs of each therapy are examined. For each drug, the cost/mg, the cost/mg/m2 and the cost/therapy (according to its duration) are evaluated according to the prices reported in the Italian Directory of Medicines and Manufacturers, 63rd Edition, November 2003.

Original languageEnglish
Pages (from-to)563-576
Number of pages14
JournalAnticancer Research
Volume25
Issue number1 B
Publication statusPublished - Jan 2005

Fingerprint

Colorectal Neoplasms
Neoplasm Metastasis
Costs and Cost Analysis
Therapeutics
Directories
Western World
Pharmaceutical Preparations
Cause of Death
Neoplasms
Adenocarcinoma
Clinical Trials
Survival
Liver

Keywords

  • Chemotherapy
  • Colorectal cancer
  • Metastases
  • Review

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Pasetto, L. M., Jirillo, A., Iadicicco, G., Rossi, E., Paris, M. K., & Monfardini, S. (2005). FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Research, 25(1 B), 563-576.

FOLFOX versus FOLFIRI : A comparison of regimens in the treatment of colorectal cancer metastases. / Pasetto, Lara Maria; Jirillo, Antonio; Iadicicco, Girolama; Rossi, Elena; Paris, Myriam Katja; Monfardini, Silvio.

In: Anticancer Research, Vol. 25, No. 1 B, 01.2005, p. 563-576.

Research output: Contribution to journalArticle

Pasetto, LM, Jirillo, A, Iadicicco, G, Rossi, E, Paris, MK & Monfardini, S 2005, 'FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases', Anticancer Research, vol. 25, no. 1 B, pp. 563-576.
Pasetto LM, Jirillo A, Iadicicco G, Rossi E, Paris MK, Monfardini S. FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases. Anticancer Research. 2005 Jan;25(1 B):563-576.
Pasetto, Lara Maria ; Jirillo, Antonio ; Iadicicco, Girolama ; Rossi, Elena ; Paris, Myriam Katja ; Monfardini, Silvio. / FOLFOX versus FOLFIRI : A comparison of regimens in the treatment of colorectal cancer metastases. In: Anticancer Research. 2005 ; Vol. 25, No. 1 B. pp. 563-576.
@article{f53a4fb14f154de2bde40871b1ed5b50,
title = "FOLFOX versus FOLFIRI: A comparison of regimens in the treatment of colorectal cancer metastases",
abstract = "Colorectal adenocarcinoma ranks second as a cause of death due to cancer in the Western world. Already at the time of the primary tumor, 15-25{\%} of the patients present with liver metastases while another 20{\%} will develop metastasis following treatment of the colorectal primary. Without any treatment the median survival after the detection of metastases is approximately 9 months, depending on the extent of the disease at the time of diagnosis. Clinical trials with the {"}FOLFOX and FOLFIRI families{"} of drugs, designed for the treatment of metastatic colorectal cancer, their results and the costs of each therapy are examined. For each drug, the cost/mg, the cost/mg/m2 and the cost/therapy (according to its duration) are evaluated according to the prices reported in the Italian Directory of Medicines and Manufacturers, 63rd Edition, November 2003.",
keywords = "Chemotherapy, Colorectal cancer, Metastases, Review",
author = "Pasetto, {Lara Maria} and Antonio Jirillo and Girolama Iadicicco and Elena Rossi and Paris, {Myriam Katja} and Silvio Monfardini",
year = "2005",
month = "1",
language = "English",
volume = "25",
pages = "563--576",
journal = "Anticancer Research",
issn = "0250-7005",
publisher = "International Institute of Anticancer Research",
number = "1 B",

}

TY - JOUR

T1 - FOLFOX versus FOLFIRI

T2 - A comparison of regimens in the treatment of colorectal cancer metastases

AU - Pasetto, Lara Maria

AU - Jirillo, Antonio

AU - Iadicicco, Girolama

AU - Rossi, Elena

AU - Paris, Myriam Katja

AU - Monfardini, Silvio

PY - 2005/1

Y1 - 2005/1

N2 - Colorectal adenocarcinoma ranks second as a cause of death due to cancer in the Western world. Already at the time of the primary tumor, 15-25% of the patients present with liver metastases while another 20% will develop metastasis following treatment of the colorectal primary. Without any treatment the median survival after the detection of metastases is approximately 9 months, depending on the extent of the disease at the time of diagnosis. Clinical trials with the "FOLFOX and FOLFIRI families" of drugs, designed for the treatment of metastatic colorectal cancer, their results and the costs of each therapy are examined. For each drug, the cost/mg, the cost/mg/m2 and the cost/therapy (according to its duration) are evaluated according to the prices reported in the Italian Directory of Medicines and Manufacturers, 63rd Edition, November 2003.

AB - Colorectal adenocarcinoma ranks second as a cause of death due to cancer in the Western world. Already at the time of the primary tumor, 15-25% of the patients present with liver metastases while another 20% will develop metastasis following treatment of the colorectal primary. Without any treatment the median survival after the detection of metastases is approximately 9 months, depending on the extent of the disease at the time of diagnosis. Clinical trials with the "FOLFOX and FOLFIRI families" of drugs, designed for the treatment of metastatic colorectal cancer, their results and the costs of each therapy are examined. For each drug, the cost/mg, the cost/mg/m2 and the cost/therapy (according to its duration) are evaluated according to the prices reported in the Italian Directory of Medicines and Manufacturers, 63rd Edition, November 2003.

KW - Chemotherapy

KW - Colorectal cancer

KW - Metastases

KW - Review

UR - http://www.scopus.com/inward/record.url?scp=16444372377&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=16444372377&partnerID=8YFLogxK

M3 - Article

C2 - 15816629

AN - SCOPUS:16444372377

VL - 25

SP - 563

EP - 576

JO - Anticancer Research

JF - Anticancer Research

SN - 0250-7005

IS - 1 B

ER -